Significance of Philadelphia Chromosome in Chronic Myeloid Leukemia Patients of Anmol Hospital, Lahore, Pakistan

Kanwal  Rashid; Amber  Hassan; Imrana  Tanvir; Kashifa  Ehsan

doi:10.52229/pbmj.v1i1.47

Authors

Kanwal Rashid University of Veterinary and Animal Sciences, Lahore, Pakistan
Amber Hassan Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan
Imrana Tanvir Pathology Department, King Abdul Aziz University, Rabigh, Saudi Arabia
Kashifa Ehsan Federal Postgraduate Medical Institute, Sheikh Zayed Medical Complex, Lahore

DOI:

https://doi.org/10.52229/pbmj.v1i1.47

Abstract

Background:Chronic myelogenous Leukemia is a form of cancer that was firstly recognizes to associate strongly with the chromosomal abnormality [t (9; 22) translocation] called Philadelphia chromosome. Objective:Philadelphia chromosome is a characteristic chromosomal marker that is associated with chronic myelogenous leukemia. Methods:More than one hundred patients of either sex were selected for the experiment.RNA was isolated from whole blood of patients so can use exclusively in RT-PCR.Results:Philadelphia chromosome in blood samples of patients with suspected diagnosis of CML was detected in 63% of patients. During our experimental studies on CML patients we do not encounter any complex translocation involving chromosome 8, 9 and 22. Conclusions:Philadelphia chromosome is a precise cytogenetic marker the detection of which is significant for differential diagnosis and clinical organization of patients with clinical diagnosis of CML. It is of significant that Ph chromosome occurs in pre-leukemic stage and has great diagnostic significance.

References

AMC. What is Chronic myeloid leukemia? American cancer society 2018.

Ottersbach CMaK. Molecular processes involved in B cell acute lymphoblastic leukaemia. PMC 2017.

Philip A Thompson HK, and Jorge E Cortes, . Diagnosis and Treatment of Chronic Myeloid Leukemia (CML) in 2015. PMC 2015.

Nordqvist C. Leukemia. medical news today 2017.

Kristine B, Judy, K., and Kathy, T. Cancer, Genes and inherited Predispositions overview Cancer Genetics 1. Center of genetics Educations 1994-2012.

Savona MaS, G. Identifying the Time to Change BCR-ABL Inhibitor Therapy in Patients with Chronic Myeloid Leukemia”. pubmed 2013.

Lewalle PaM, P. The impact of molecular biology techniques on the management of newly diagnosed chronic myeloid leukemia patients in chronic phase. A review. Science direct 2013; 49.

Ahmedin Jemal FBMMCMJFMEWDF. Global cancer statistics. J cancer clin 2011; 61(2).

Singh H, Shelat, A., Singh, A., Boulos, N., Williams, R. and Guy, R.,. A Screening-Based Approach to Circumvent Tumor Microenvironment-Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia. Pubmed 2014.

Savage D, Szydlo, RM. and Goldman, JM., . Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral center 16-year period. Pubmed 1997.

WALID AL-ACHKAR AW, 1 ADNAN IKHTIAR,2 and THOMAS LIEHR3. Three-way Philadelphia translocation t(9;10;22)(q34;p11.2;q11.2) as a secondary abnormality in an imatinib mesylate-resistant chronic myeloid leukemia patient. PMC 2013.

Oudat R, Ogeilat T, AlZghoul A, Khawaldeh M, Badwan S. Chronic Myeloid Leukaemia with Extreme Thrombocytosis and T315I BCR-ABL Kinase Domain Mutation: A Case Report. JOURNAL OF THE ROYAL MEDICAL SERVICES 2019; 26(3): 92.

Mcligeyo AA. Ctopenia Following Imatinib Treatment of Chronic Myeloid Leukemia (Cml) in Kenya: a Study at Gipap Clinic, Nairobi Hospital: University of Nairobi; 2018.

Thomas X, Heiblig M. The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment. Expert opinion on drug discovery 2016; 11(11): 1061-70.

Borges CdS, Ferreira AF, Almeida VH, et al. Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia. Experimental Hematology 2018; 66: 50-62.

Kinstrie R, Karamitros D, Goardon N, et al. Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia. Blood advances 2016; 1(3): 160-9.

H Zhou, 2 P Y Mak,1 H Mu,1 D H Mak,1 Z Zeng,1 J Cortes,3 Q Liu,2 M Andreeff,1,* and B Z Carter1,*. Combined inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. PMC 2017.

Yang J, Ikezoe, T., Nishioka, C., Udaka, K., and Yokoyama, A. Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling. international journal of cancer 2013; 134(5).

Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. pubmed 20006.

Tsuzuki M, Handa., K., Yamamoto, K., Hasegawa, A., Watanabe, M., Yamamoto, Y., Mizuta, S., Maruyama, F., Okamoto, M., Emi., N., and Ezaki, K.,. Chronic myeloid leukemia following chemotherapy with 5'-deoxy-5-fluorouridine for gastric cancer. pubmed 2008.